Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lobeglitazone for NAFLD in Type 2 Diabetes
NCT02285205Phase 4Completed
- Sponsor
- Yonsei University
- Start
- Nov 2014
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of lobeglitazone in non-alcoholic fatty liver disease (NAFLD), sponsored by Yonsei University. Started Nov 2014; status: completed.
02
Drugs
lobeglitazone
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02285205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02285205.